View More View Less
  • 1 Országos Onkológiai Intézet Nőgyógyászati Osztály Budapest Ráth Gy. u. 7–9. 1122
Restricted access

Purchase article

USD  $25.00

1 year subscription (Individual Only)

USD  $1,070.00

A petefészekrákok második vonalú kemoterápiáival 2,3–42 hónapos progressziómentes túlélésekről lehet olvasni. Célkitűzés: A szerzők a második vonalú paclitaxel-carboplatin-, topotecan-, és cisplatin-epirubicin-etoposid kemoterápiákat értékelték. Módszer: A paclitaxel-carboplatin kombinációt 13 beteg 3 hetente 175 mg/m 2 , illetőleg AUC 5-dózisban, a topotecant 16 beteg 3 hetente, 1,5 mg/m 2 /1–5 nap dózisban, a cisplatin-epirubicin-etoposid kombinációt (33 mg/m 2 /1–3 nap – 60 mg/m 2 /1 nap – 100 mg/m 2 /1–3 nap) pedig 4 hetenként 48 beteg kapta. A progressziómentes túlélés statisztikai értékelése a Kaplan–Meier-féle product-limit eljárás szerint történt. Eredmények: A paclitaxel-carboplatin és a cisplatin-epirubicin-etoposid kemoterápiákkal a topotecanhoz képest szignifikánsan jobb progressziómentes időszak (5 és 5,5 hónap vs 4 hónap, p = 0,0324 és p = 0,0087) igazolódott, és mindhárom kezelés jobb progressziómentes időszakot (6 és 3,5 hónap, 7 és 4 hónap ill. 6,5 és 3,5 hónap) eredményezett a platinaérzékeny betegekben, mint a platinarezisztensekben. Következtetés: Az alacsonyabb árú cisplatin-epirubicin-etoposid kombinációval a másik 2 kezeléshez képest valamivel jobb eredmény figyelhető meg platinaérzékeny és platinarezisztens daganatokban is.

  • Ostoros Gy.: A tüdőrák és a mellhártya elsődleges rosszindulatú megbetegedéseinek diagnosztikája és kezelése. Irányelvek 2001. Medicina Thoracalis, 2001, 54 , 1–24.

    Ostoros Gy. , 'A tüdőrák és a mellhártya elsődleges rosszindulatú megbetegedéseinek diagnosztikája és kezelése. Irányelvek 2001 ' (2001 ) 54 Medicina Thoracalis : 1 -24.

    • Search Google Scholar
  • Harries, M, Gore, M.: Chemotherapy for epithelial ovarian cancer-treatment of recurrent disease. Lancet Oncol., 2002, 3 , 537–545.

    Gore M. , 'Chemotherapy for epithelial ovarian cancer-treatment of recurrent disease ' (2002 ) 3 Lancet Oncol. : 537 -545.

    • Search Google Scholar
  • Langmar Z., Csomor S.: A hámereretű malignus petefészek-daganatok kezelése. Orv. Hetil., 2006, 147 , 1627–1632.

    Csomor S. , 'A hámereretű malignus petefészek-daganatok kezelése ' (2006 ) 147 Orv. Hetil. : 1627 -1632.

    • Search Google Scholar
  • Alberts, D. S.: Treatment of refractory and recurrent ovarian cancer. Semin. Oncol., 1999, 26 (1 Suppl 1) , 8–14.

    Alberts D. S. , 'Treatment of refractory and recurrent ovarian cancer ' (1999 ) 26 Semin. Oncol. : 8 -14.

    • Search Google Scholar
  • Zanotti, K. M., Belinson, J. L., Kennedy, A. W. és mtsai: Treatment of relapsed carcinoma of the ovary with single-agent paclitaxel following exposure to paclitaxel and platinum employed as initial therapy. Gynecol. Oncol., 2000, 79 , 211–215.

    Kennedy A. W. , 'Treatment of relapsed carcinoma of the ovary with single-agent paclitaxel following exposure to paclitaxel and platinum employed as initial therapy ' (2000 ) 79 Gynecol. Oncol. : 211 -215.

    • Search Google Scholar
  • Hernádi Z., Huga S., Lukácskó L. és mtsai: Rezisztencia a petefészekrákos betegek platina-bázisú kemoterápiája során – a paclitaxel mint kezelési lehetőség. Magy. Nőorv. L., 2001, 64 , 249–254.

    Lukácskó L. , 'Rezisztencia a petefészekrákos betegek platina-bázisú kemoterápiája során – a paclitaxel mint kezelési lehetőség ' (2001 ) 64 Magy. Nőorv. L. : 249 -254.

    • Search Google Scholar
  • Cantù, M. G., Buda, A., Parma, G. és mtsai: Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens. J. Clin. Oncol., 2002, 20 , 1232–1237.

    Parma G. , 'Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens ' (2002 ) 20 J. Clin. Oncol. : 1232 -1237.

    • Search Google Scholar
  • Dizon, D. S., Hensley, M. L., Poynor, E. A. és mtsai: Retrospective Analysis of Carboplatin and Paclitaxel as Initial Second-Line Therapy for Recurrent Epithelial Ovarian Carcinoma, Application Toward a Dynamic Disease State Model of Ovarian Cancer. J. Clin. Oncol., 2002, 20 , 1238–1247.

    Poynor E. A. , 'Retrospective Analysis of Carboplatin and Paclitaxel as Initial Second-Line Therapy for Recurrent Epithelial Ovarian Carcinoma, Application Toward a Dynamic Disease State Model of Ovarian Cancer ' (2002 ) 20 J. Clin. Oncol. : 1238 -1247.

    • Search Google Scholar
  • Dizon, D. S., Dupont, J., Anderson, S., Sabbatini, P. és mtsai: Treatment of recurrent ovarian cancer, a retrospective analysis of women treated with single-agent carboplatin originally treated with carboplatin and paclitaxel. The Memorial Sloan-Kettering Cancer Center experience. Gynecol. Oncol., 2003, 91 , 584–590.

    Sabbatini P. , 'Treatment of recurrent ovarian cancer, a retrospective analysis of women treated with single-agent carboplatin originally treated with carboplatin and paclitaxel. The Memorial Sloan-Kettering Cancer Center experience ' (2003 ) 91 Gynecol. Oncol. : 584 -590.

    • Search Google Scholar
  • Gronlund, B., Hogdall, C., Hansen, H. H. és mtsa: Results of reinduction therapy with paclitaxel and carboplatin in recurrent epithelial ovarian cancer. Gynecol. Oncol., 2001, 83 , 128–134.

    Hansen H. H. , 'Results of reinduction therapy with paclitaxel and carboplatin in recurrent epithelial ovarian cancer ' (2001 ) 83 Gynecol. Oncol. : 128 -134.

    • Search Google Scholar
  • Parmar, M. K., Ledermann, J. A., Colombo, N. és mtsai: Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer, the ICON4/AGO-OVAR-2.2 trial. Lancet, 2003, 361 , 2099–106.

    Colombo N. , 'Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer, the ICON4/AGO-OVAR-2.2 trial ' (2003 ) 361 Lancet : 2099 -106.

    • Search Google Scholar
  • ten Bokkel, H. W., Gore, M., Carmichael, J., és mtsai.: Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J. Clin. Oncol., 1997, 15 , 2183–2193.

    Carmichael J. , 'Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer ' (1997 ) 15 J. Clin. Oncol. : 2183 -2193.

    • Search Google Scholar
  • McGuire, W. P., Blessing, J. A., Bookman, M. A. és mtsai.: Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma. A Gynecologic Oncology Group Study. J. Clin. Oncol., 2000, 18 , 1062–1067.

    Bookman M. A. , 'Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma. A Gynecologic Oncology Group Study ' (2000 ) 18 J. Clin. Oncol. : 1062 -1067.

    • Search Google Scholar
  • Gronlund, B., Hansen, H. H., Hogdall, C. és mtsa: Efficacy of low-dose topotecan in second-line treatment for patients with epithelial ovarian carcinoma. Cancer, 2002, 95 , 1656–1662.

    Hogdall C. , 'Efficacy of low-dose topotecan in second-line treatment for patients with epithelial ovarian carcinoma ' (2002 ) 95 Cancer : 1656 -1662.

    • Search Google Scholar
  • Gordon, A. N., Fleagle, J. T., Gurthrie, D. és mtsai: Recurrent epithelial ovarian carcinoma, a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J. Clin. Oncol., 2001, 19 , 3312–3322.

    Gurthrie D. , 'Recurrent epithelial ovarian carcinoma, a randomized phase III study of pegylated liposomal doxorubicin versus topotecan ' (2001 ) 19 J. Clin. Oncol. : 3312 -3322.

    • Search Google Scholar
  • Bookman, M. A., Malmstrom, H., Bolis, G. és mtsai: Topotecan for the treatment of advanced epithelial ovarian cancer, an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J. Clin. Oncol., 1998, 16 , 3345–3352.

    Bolis G. , 'Topotecan for the treatment of advanced epithelial ovarian cancer, an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel ' (1998 ) 16 J. Clin. Oncol. : 3345 -3352.

    • Search Google Scholar
  • Wilailak, S., Linasmita, V.: A study of pegylated liposomal doxorubicin in platinum-refractory epithelial ovarian cancer. Oncology, 2004, 67 , 183–186.

    Linasmita V. , 'A study of pegylated liposomal doxorubicin in platinum-refractory epithelial ovarian cancer ' (2004 ) 67 Oncology : 183 -186.

    • Search Google Scholar
  • Rose, P. G., Maxson, J. H., Fusco, N. és mtsai: Liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma, a retrospective comparative study of single-agent dosages. Gynecol. Oncol., 2001, 82 , 323–328.

    Fusco N. , 'Liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma, a retrospective comparative study of single-agent dosages ' (2001 ) 82 Gynecol. Oncol. : 323 -328.

    • Search Google Scholar
  • Thigpen, J. T., Aghajanian, C. A., Alberts, D. S. és mtsai: Role of pegylated liposomal doxorubicin in ovarian cancer. Gynecol. Oncol., 2005, 96 , 10–18.

    Alberts D. S. , 'Role of pegylated liposomal doxorubicin in ovarian cancer ' (2005 ) 96 Gynecol. Oncol. : 10 -18.

    • Search Google Scholar
  • Thigpen, J. T.: Ovaries and fallopian tubes. In: Clinical Oncology. 3rd Edition. Eds. Abeloff, M. D., Armitage, J. O., Niederhuber, J. E., McKenna, W. G. és mtsai. Elsevier, Philadelphia, 2004, 2311–2346.

    Thigpen J. T. , '', in Clinical Oncology , (2004 ) -.

  • Barker, G. H., Wiltshaw, E.: Use of high dose cis-dichlorodiammine platinum (II) (NSC-119875) following failure on previous chemotherapy for advanced carcinoma of the ovary. Br. J. Obstet. Gynaecol., 1981, 88 , 1192–1199.

    Wiltshaw E. , 'Use of high dose cis-dichlorodiammine platinum (II) (NSC-119875) following failure on previous chemotherapy for advanced carcinoma of the ovary ' (1981 ) 88 Br. J. Obstet. Gynaecol. : 1192 -1199.

    • Search Google Scholar
  • Pfisterer, J., Plante, M., Vergote, I. és mtsai: Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer, an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J. Clin. Oncol., 2006, 24 , 4699–4707.

    Vergote I. , 'Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer, an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG ' (2006 ) 24 J. Clin. Oncol. : 4699 -4707.

    • Search Google Scholar
  • DiSaia, P. J., Creasman, W. T.: Clinical gynecologic oncology. 6th edition. Mosby Inc. St. Louis-London-Philadelphia, 2002, 351–377.

    Creasman W. T. , '', in Clinical gynecologic oncology , (2002 ) -.

  • Rose, P. G., Blessing, J. A., Mayer, A. R. és mtsa: Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma. Gynecologic Oncology Group study. J. Clin. Oncol., 1998, 16 , 405–410.

    Mayer A. R. , 'Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma. Gynecologic Oncology Group study ' (1998 ) 16 J. Clin. Oncol. : 405 -410.

    • Search Google Scholar
  • Ozols, R. F.: Oral etoposide for the treatment of recurrent ovarian cancer. Drugs, 1999, 58, Suppl. 3 , 43–49.

    Ozols R. F. , 'Oral etoposide for the treatment of recurrent ovarian cancer ' (1999 ) 58 Drugs : 43 -49.

    • Search Google Scholar
  • Alici, S., Saip, P., Eralp, Y. és mtsai: Oral etoposide (VP16) in platinum-resistant epithelial ovarian cancer (EOC). Am. J. Clin. Oncol., 2003, 26 , 358–362.

    Eralp Y. , 'Oral etoposide (VP16) in platinum-resistant epithelial ovarian cancer (EOC) ' (2003 ) 26 Am. J. Clin. Oncol. : 358 -362.

    • Search Google Scholar
  • Iacobelli, S., Irtelli, L., Sacco, R. és mtsai: A phase II study of neoadjuvant chemotherapy with cisplatin epirubicin and VP-16 for stage III unresectable non-small cell lung cancer. Anticancer Res., 1998, 18 , 2081–2084.

    Sacco R. , 'A phase II study of neoadjuvant chemotherapy with cisplatin epirubicin and VP-16 for stage III unresectable non-small cell lung cancer ' (1998 ) 18 Anticancer Res. : 2081 -2084.

    • Search Google Scholar
  • Gridelli, C., Iacobelli, S., Martino, T. és mtsai: Neoadjuvant chemotherapy with cisplatin, epirubicin and VP-16 for stage IIIA–IIIB non-small-cell lung cancer, a pilot study. Tumori, 1992, 78 , 377–379.

    Martino T. , 'Neoadjuvant chemotherapy with cisplatin, epirubicin and VP-16 for stage IIIA–IIIB non-small-cell lung cancer, a pilot study ' (1992 ) 78 Tumori : 377 -379.

    • Search Google Scholar
  • Szondi K.: A kissejtes tüdőrák kemoterápiája. Magy. Onkol., 2000, 44 , 221–225.

    Szondi K. , 'A kissejtes tüdőrák kemoterápiája ' (2000 ) 44 Magy. Onkol. : 221 -225.

  • Ostoros Gy.: A nagy dilemma, a nem kissejtes tüdőrák kemoterápiája. Magy. Onkol., 2000, 44 , 215–220.

    Ostoros Gy. , 'A nagy dilemma, a nem kissejtes tüdőrák kemoterápiája ' (2000 ) 44 Magy. Onkol. : 215 -220.

    • Search Google Scholar
  • Wils, J., Utama, I., Smeets, J.: Chemotherapy consisting of epirubicin, cisplatin, and etoposide followed by irradiation in stage III non-small cell lung cancer and chemotherapy alone in stage IV non-small cell lung cancer. Oncology, 1988, 45 , 413–416.

    Smeets J. , 'Chemotherapy consisting of epirubicin, cisplatin, and etoposide followed by irradiation in stage III non-small cell lung cancer and chemotherapy alone in stage IV non-small cell lung cancer ' (1988 ) 45 Oncology : 413 -416.

    • Search Google Scholar

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
Oct 2020 2 0 0
Nov 2020 4 0 0
Dec 2020 5 0 0
Jan 2021 7 0 0
Feb 2021 11 0 0
Mar 2021 4 1 1
Apr 2021 1 0 0